Goldman Sachs’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Goldman Sachs’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,719,000	Closed	-$952K	–	7324
2016 Q3	$952K	Buy	+2,719,000	New	+$952K	﹤0.01%	4445
2014 Q4	–	Sell	-140,000	Closed	-$288K	–	7615
2014 Q3	$288K	Hold	140,000	–	–	﹤0.01%	5790
2014 Q2	$428K	Hold	140,000	–	–	﹤0.01%	5463
2014 Q1	$350K	Hold	140,000	–	–	﹤0.01%	5607
2013 Q4	$694K	Buy	+140,000	New	+$694K	﹤0.01%	5048

Goldman Sachs's RXII Position: Q4 2016 in Review

Goldman Sachs sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,472,527 shares — an estimated $516K sold.

Goldman Sachs first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $823K in Q2 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

Goldman Sachs reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 1,472,527 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $516K.
Goldman Sachs first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
Goldman Sachs's GALENA BIOPHARMA INC COM position peaked at $823K in Q2 2013.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.